Holter-guided identification of premature ventricular contractions susceptible to suppression by β-blockers

Maria Vittoria Pitzalis, Filippo Mastropasqua, Francesco Massari, Paolo Totaro, Marinella Di Maggio, Paolo Rizzon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To evaluate whether the identification of the different types of relations between premature ventricular contractions (PVCs) and the preceding sinus cycle length is capable of predicting the effect of β-blockers on the PVCs themselves, 55 patients (43 men, 12 women, mean age 52.6 ± 15.6 years) with different cardiac diseases, and >30 PVCs/hr characterized by stability and the same relation at two Holter monitoring periods were studied. The relation was tachycardia enhanced (the shorter the preceding cycle length, the higher the incidence of PVCs) in 23 patients (group 1); indifferent (no correlation between the preceding cycle length and PVC incidence) in 21 (group 2); and bradycardia enhanced (the longer the preceding cycle length, the higher the incidence of PVCs) in 11 (group 3). A third Holter monitoring was performed 6 days after nadolol administration (80 mg/day) to evaluate its effect on the three types of PVCs. In group 1, nadolol caused a reduction in the PVC incidence in all patients (-88%; p <0.001). In group 2, it caused a reduction in the majority of patients (-60%; p <0.05) but an increase in five. In group 3, it caused a reduction in only half of the patients (-45%) and a 91% increase in the remainder. The difference in the effect of nadolol in the three groups was highly significant (χ2 = 27.5; p <0.0001). The relation between the incidence of PVCs and the preceding cycle length is e useful means of identifying subsets of patients with PVCs who will benefit from β-blockers.

Original languageEnglish
Pages (from-to)508-515
Number of pages8
JournalAmerican Heart Journal
Volume131
Issue number3
DOIs
Publication statusPublished - 1996

Fingerprint

Ventricular Premature Complexes
Nadolol
Incidence
Ambulatory Electrocardiography
Bradycardia
Tachycardia
Heart Diseases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Holter-guided identification of premature ventricular contractions susceptible to suppression by β-blockers. / Pitzalis, Maria Vittoria; Mastropasqua, Filippo; Massari, Francesco; Totaro, Paolo; Di Maggio, Marinella; Rizzon, Paolo.

In: American Heart Journal, Vol. 131, No. 3, 1996, p. 508-515.

Research output: Contribution to journalArticle

Pitzalis, Maria Vittoria ; Mastropasqua, Filippo ; Massari, Francesco ; Totaro, Paolo ; Di Maggio, Marinella ; Rizzon, Paolo. / Holter-guided identification of premature ventricular contractions susceptible to suppression by β-blockers. In: American Heart Journal. 1996 ; Vol. 131, No. 3. pp. 508-515.
@article{7a0da3d45b2942b2b18a7e649c173fbc,
title = "Holter-guided identification of premature ventricular contractions susceptible to suppression by β-blockers",
abstract = "To evaluate whether the identification of the different types of relations between premature ventricular contractions (PVCs) and the preceding sinus cycle length is capable of predicting the effect of β-blockers on the PVCs themselves, 55 patients (43 men, 12 women, mean age 52.6 ± 15.6 years) with different cardiac diseases, and >30 PVCs/hr characterized by stability and the same relation at two Holter monitoring periods were studied. The relation was tachycardia enhanced (the shorter the preceding cycle length, the higher the incidence of PVCs) in 23 patients (group 1); indifferent (no correlation between the preceding cycle length and PVC incidence) in 21 (group 2); and bradycardia enhanced (the longer the preceding cycle length, the higher the incidence of PVCs) in 11 (group 3). A third Holter monitoring was performed 6 days after nadolol administration (80 mg/day) to evaluate its effect on the three types of PVCs. In group 1, nadolol caused a reduction in the PVC incidence in all patients (-88{\%}; p <0.001). In group 2, it caused a reduction in the majority of patients (-60{\%}; p <0.05) but an increase in five. In group 3, it caused a reduction in only half of the patients (-45{\%}) and a 91{\%} increase in the remainder. The difference in the effect of nadolol in the three groups was highly significant (χ2 = 27.5; p <0.0001). The relation between the incidence of PVCs and the preceding cycle length is e useful means of identifying subsets of patients with PVCs who will benefit from β-blockers.",
author = "Pitzalis, {Maria Vittoria} and Filippo Mastropasqua and Francesco Massari and Paolo Totaro and {Di Maggio}, Marinella and Paolo Rizzon",
year = "1996",
doi = "10.1016/S0002-8703(96)90529-3",
language = "English",
volume = "131",
pages = "508--515",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Holter-guided identification of premature ventricular contractions susceptible to suppression by β-blockers

AU - Pitzalis, Maria Vittoria

AU - Mastropasqua, Filippo

AU - Massari, Francesco

AU - Totaro, Paolo

AU - Di Maggio, Marinella

AU - Rizzon, Paolo

PY - 1996

Y1 - 1996

N2 - To evaluate whether the identification of the different types of relations between premature ventricular contractions (PVCs) and the preceding sinus cycle length is capable of predicting the effect of β-blockers on the PVCs themselves, 55 patients (43 men, 12 women, mean age 52.6 ± 15.6 years) with different cardiac diseases, and >30 PVCs/hr characterized by stability and the same relation at two Holter monitoring periods were studied. The relation was tachycardia enhanced (the shorter the preceding cycle length, the higher the incidence of PVCs) in 23 patients (group 1); indifferent (no correlation between the preceding cycle length and PVC incidence) in 21 (group 2); and bradycardia enhanced (the longer the preceding cycle length, the higher the incidence of PVCs) in 11 (group 3). A third Holter monitoring was performed 6 days after nadolol administration (80 mg/day) to evaluate its effect on the three types of PVCs. In group 1, nadolol caused a reduction in the PVC incidence in all patients (-88%; p <0.001). In group 2, it caused a reduction in the majority of patients (-60%; p <0.05) but an increase in five. In group 3, it caused a reduction in only half of the patients (-45%) and a 91% increase in the remainder. The difference in the effect of nadolol in the three groups was highly significant (χ2 = 27.5; p <0.0001). The relation between the incidence of PVCs and the preceding cycle length is e useful means of identifying subsets of patients with PVCs who will benefit from β-blockers.

AB - To evaluate whether the identification of the different types of relations between premature ventricular contractions (PVCs) and the preceding sinus cycle length is capable of predicting the effect of β-blockers on the PVCs themselves, 55 patients (43 men, 12 women, mean age 52.6 ± 15.6 years) with different cardiac diseases, and >30 PVCs/hr characterized by stability and the same relation at two Holter monitoring periods were studied. The relation was tachycardia enhanced (the shorter the preceding cycle length, the higher the incidence of PVCs) in 23 patients (group 1); indifferent (no correlation between the preceding cycle length and PVC incidence) in 21 (group 2); and bradycardia enhanced (the longer the preceding cycle length, the higher the incidence of PVCs) in 11 (group 3). A third Holter monitoring was performed 6 days after nadolol administration (80 mg/day) to evaluate its effect on the three types of PVCs. In group 1, nadolol caused a reduction in the PVC incidence in all patients (-88%; p <0.001). In group 2, it caused a reduction in the majority of patients (-60%; p <0.05) but an increase in five. In group 3, it caused a reduction in only half of the patients (-45%) and a 91% increase in the remainder. The difference in the effect of nadolol in the three groups was highly significant (χ2 = 27.5; p <0.0001). The relation between the incidence of PVCs and the preceding cycle length is e useful means of identifying subsets of patients with PVCs who will benefit from β-blockers.

UR - http://www.scopus.com/inward/record.url?scp=0029866365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029866365&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(96)90529-3

DO - 10.1016/S0002-8703(96)90529-3

M3 - Article

VL - 131

SP - 508

EP - 515

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -